After the Bell
Before the Bell
Jim Cramer's Daily Booyah
Winners & Losers
This small-cap company's shares are half where they ended 2015.
The uptick in the small- and mid-cap space bodes well for future capital appreciation.
The biotechnology company, which makes alcoholism drug Horizant, was acquired by privately held Arbor Pharmaceuticals for $467 million in cash, a price lower than at least one analyst expected.
XenoPort (XNPT) shares are soaring Monday as Arbor Pharmaceuticals agreed to acquire the company in a deal valued at about $467 million.
©1996-2016 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.